New England Patriots release DT Jeremiah Pharms Jr

The Patriots' cut of defensive tackle Jeremiah Pharms Jr earns a D+ Contract Value Index (CVI), reflecting a transaction that clears modest salary without meaningful roster impact. At $1.09M AAV against a $4.35M total commitment, Pharms Jr represented replacement-level depth on the interior defensive line—the kind of rotational body that generates little leverage and no reluctance to move on from. For a team currently positioned as the AFC East's #2 seed heading into the regular season, releasing a non-impact defensive lineman is a low-consequence housekeeping move that opens just under $1.1M in immediate cap relief. The CVI penalty here stems not from poor contract architecture—the deal itself was modest and reasonable for a depth piece—but from the reality that Pharms Jr never developed into enough of a contributor to justify retention, leaving the organization with a sunk asset rather than a salvageable one. In the context of roster construction during the offseason, this cut is neither a strategic masterstroke nor a damning indictment; it's simply a franchise recognizing that limited playing time and production didn't warrant ongoing investment, even at a bargain rate.